Chimeric Therapeutics Limited (ASX:CHM)
Australia · Delayed Price · Currency is AUD 0.0030
0.00 (0.00%)
Sep 30, 2026, 4:11 PM AEST
Chimeric Therapeutics Cash Flow Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Net Income | -18.81 | -10.43 | -12.53 | -25.92 | -15.9 |
Depreciation & Amortization | 0.52 | 1.03 | 1.08 | 0.97 | 0.95 |
Loss (Gain) From Sale of Assets | - | 0 | 0.01 | 0 | 0 |
Asset Writedown & Restructuring Costs | - | -0.09 | 1.26 | - | - |
Stock-Based Compensation | - | 1.09 | 0.89 | 3.32 | 3.17 |
Other Operating Activities | 7.51 | -0.6 | 0.15 | 1.47 | 0.84 |
Change in Accounts Receivable | - | -0.01 | 3.56 | -0.99 | -2.63 |
Change in Accounts Payable | - | 1.94 | -1.98 | 4.74 | 0.32 |
Change in Other Net Operating Assets | - | -0.2 | 0.01 | 0.1 | 0.1 |
Operating Cash Flow | -10.78 | -7.28 | -7.54 | -16.31 | -13.15 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Capital Expenditures | - | - | - | - | -0.01 |
Sale (Purchase) of Intangibles | -0.25 | - | - | -0.11 | -0.53 |
Investment in Securities | - | - | - | - | -0.04 |
Investing Cash Flow | -0.25 | - | - | -0.11 | -0.58 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Short-Term Debt Issued | 0.75 | - | - | - | - |
Long-Term Debt Issued | 1.79 | - | - | - | - |
Total Debt Issued | 2.54 | - | - | - | - |
Long-Term Debt Repaid | -4.17 | - | -2.28 | -2.23 | -4.05 |
Total Debt Repaid | -4.17 | - | -2.28 | -2.23 | -4.05 |
Net Debt Issued (Repaid) | -1.63 | - | -2.28 | -2.23 | -4.05 |
Issuance of Common Stock | 8.79 | 8.2 | 11.74 | 2.58 | 14.9 |
Other Financing Activities | -1.08 | 1.84 | -1.21 | -0.1 | -1.31 |
Financing Cash Flow | 6.08 | 10.05 | 8.26 | 0.25 | 9.54 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Foreign Exchange Rate Adjustments | -0.01 | -0.07 | -0.03 | 0.15 | 0.16 |
Net Cash Flow | -4.96 | 2.7 | 0.69 | -16.02 | -4.03 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -10.78 | -7.28 | -7.54 | -16.31 | -13.17 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | - | -57.36% | -101.07% | -361.89% | -503.04% |
Free Cash Flow Per Share | -0.35 | -0.54 | -1.08 | -3.76 | -3.66 |
Levered Free Cash Flow | -6.76 | -2.15 | -3.5 | -10.45 | -6.8 |
Unlevered Free Cash Flow | -6.58 | -2.02 | -3.49 | -9.97 | -6.4 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash Interest Paid | 0.1 | - | 0.01 | 0.01 | - |
Cash Income Tax Paid | -4.5 | -4.17 | -7.34 | -3.5 | - |
Change in Working Capital | - | 1.73 | 1.6 | 3.85 | -2.21 |